← 返回

CAR-T 细胞治疗中的免疫效应细胞相关神经毒性综合征

英文原题:Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.

查看英文原题

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.

PubMed 2022/08/23(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)-T细胞疗法正在成为某些血液系统恶性肿瘤治疗的重要手段。虽然CAR-T 细胞在某些血液系统恶性肿瘤中产生了强有力的应答,但与治疗相关的毒性限制了其应用。免疫效应细胞相关神经毒性综合征(ICANS)是一种可能危及生命的神经毒性,常发生于CAR-T 细胞治疗中。在此,我们将讨论ICANS、其治疗、可能的机制以及针对CAR-T 细胞疗法这一关键局限性的潜在解决方案。随着CAR-T 细胞疗法领域的发展,需要改进治疗方法和策略以规避或克服ICANS,从而改善发病率、死亡率并降低CAR-T 细胞疗法的成本。这种严重的、危及生命的副作用需要被研究,以更好地理解其机制并开发治疗方法和替代策略。

展开英文摘要原文

Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy have limited their use. Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) is a potentially life-threatening neurotoxicity that commonly occurs with CAR-T cell therapy.

Here we will discuss ICANS, its treatment, possible mechanisms, and potential solutions to this critical limitation of CAR-T cell therapy. As the field of CAR-T cell therapy evolves, improved treatments and methods to circumvent or overcome ICANS are necessary to improve morbidity, mortality, and decrease the cost of CAR-T cell therapy. This serious, life-threatening side effect needs to be studied to better understand its mechanisms and develop treatments and alternative strategies.

论文信息

作者
Sterner RC、Sterner RM
第一作者单位
School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.United States
通讯作者单位
Department of Surgery, Mayo Clinic, Rochester, MN, United States.United States
文献类型
综述
期刊
Frontiers in immunology2022
原文标识
PubMed 36081506 · DOI 10.3389/fimmu.2022.879608